SHANXI C&Y PHARMACEUTICAL GROUP CO.,LTD.

ShanXi C&Y Pharmaceutical Group Co.,LTD.

300254

CNE1000016D0

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 14/05/2024 BST			5-day change	1st Jan Change
9.29 ^CNY	-1.90%		-8.20%	-3.53%

04-12	ShanXi C&Y Pharmaceutical Group Co.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-18	ShanXi C&Y Pharmaceutical Group Co.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

ShanXi C&Y Pharmaceutical Group Co., Ltd. announced that it has received CNY 109.999995 million in funding from Caitong Fund Management Co., Ltd., Ningbo Ningju Asset Management Center (Limited Partnership), Nuode Asset Management Co., Ltd., and other investors

April 28, 2022

On April 29, 2022, ShanXi C&Y Pharmaceutical Group Co., Ltd. closed the transaction. The company has received net proceeds of CNY 104,090,397.82 in the transaction.

Latest news about ShanXi C&Y Pharmaceutical Group Co.,LTD.

ShanXi C&Y Pharmaceutical Group Co.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-12	CI
ShanXi C&Y Pharmaceutical Group Co.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2023	03-18	CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	24/10/23	CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	04/08/23	CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 184.999997 million in funding	29/06/23	CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	24/04/23	CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	24/04/23	CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/10/22	CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	25/08/22	CI
Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd. announced that it expects to receive CNY 105 million in funding from ShanXi C&Y Pharmaceutical Group Co., Ltd.	01/06/22	CI
C&Y Pharmaceutical Raises $15.5 Million in Private Placement	10/05/22	MT
ShanXi C&Y Pharmaceutical Group Co., Ltd. announced that it has received CNY 109.999995 million in funding from Caitong Fund Management Co., Ltd., Ningbo Ningju Asset Management Center (Limited Partnership), Nuode Asset Management Co., Ltd., and other investors	28/04/22	CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	28/04/22	CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	26/10/21	CI
Shanxi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	27/08/21	CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 130 million in funding from Caitong Fund Management Co., Ltd., Ningbo Ningju Asset Management Center (Limited Partnership), Nuode Asset Management Co., Ltd., and other investors	26/08/21	CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. and Chen Jinsong entered into an equity transfer agreement to acquire 15.43% stake in Sichuan C&Y Traditional Chinese Medicine Co., Ltd. from Chen Renhu and Tang Wenjing.	26/05/21	CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	26/04/21	CI
Shanxi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	26/04/21	CI
Hangzhou Pollen Group Company Limited announced that it has received CNY 115 million in funding from ShanXi C&Y Pharmaceutical Group Co., Ltd.	22/12/20	CI
Shenzhen Purcotton Technology Co. Ltd announced that it expects to receive CNY 80 million in funding from ShanXi C&Y Pharmaceutical Group Co., LTD.	26/11/20	CI
Shenzhen PureH2B Technology Co., Ltd. announced that it expects to receive CNY 100 million in funding from ShanXi C&Y Pharmaceutical Group Co., Ltd.	26/11/20	CI
Hangzhou Pollen Group Company Limited announced that it expects to receive CNY 115 million in funding from ShanXi C&Y Pharmaceutical Group Co., Ltd.	26/11/20	CI
Shanxi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	28/10/20	CI
ShanXi C&Y Pharmaceutical Group Co., LTD. announced that it has received CNY 139.999998 million in funding	11/10/20	CI

Chart ShanXi C&Y Pharmaceutical Group Co.,LTD.

Duration

Period

Chart ShanXi C&Y Pharmaceutical Group Co.,LTD.

More charts

ShanXi C&Y Pharmaceutical Group Co., Ltd. is principally engaged in the research, development, manufacture and distribution of pharmaceuticals. The Companyâs main products include anti-infective agents, respiratory system agents, cardiovascular drugs, antidepressant drugs, urinary system agents, pediatric agents and other drugs, as well as pharmaceutical raw materials and pharmaceutical intermediates. It also involves in the manufacture and distribution of health food products, as well as the provision of deoxyribonucleic acid (DNA) genetic preservation and pregnant environment testing services. The Company distributes its products in domestic market.

Sector

Pharmaceuticals

Calendar

22/05/2024 - Extraordinary Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHANXI C&Y PHARMACEUTICAL GROUP CO.,LTD.	-3.53%	311M
ELI LILLY AND COMPANY	+33.81%	709B
NOVO NORDISK A/S	+31.06%	595B
JOHNSON & JOHNSON	-2.07%	367B
MERCK & CO., INC.	+20.64%	334B
ABBVIE INC.	+5.14%	289B
ASTRAZENECA PLC	+14.43%	239B
NOVARTIS AG	+9.20%	211B
ROCHE HOLDING AG	-3.48%	203B
AMGEN INC.	+8.59%	171B